Glycemic Control and Diabetic Macular Edema
- Conditions
- Diabetic Macular Edema
- Interventions
- Other: Respond to therapy for diabetic macular edema
- Registration Number
- NCT01358396
- Lead Sponsor
- Cairo University
- Brief Summary
Does diabetic patients' glycemic control affect their response to laser and/or intravitreal injection therapy in terms of visual and anatomical outcomes.
- Detailed Description
To evaluate the visual and anatomical response to therapy in patients with diabetic macular edema (DME) in relation to their glycemic control.
Patients with DME with central foveal thickness (CFT) \> 250µm with no proliferative disease had their glycosolated hemoglobin (HbA1c) measured at baseline and 3 months. CFT by optical coherence tomography, and best corrected visual acuity (BCVA) in logMARs were measured at baseline, 1, and 3 months. Exclusion criteria: laser or intravitreal injections within 6 months, hard exudates within 500um of the foveal center, or macular traction. Therapy included laser and intravitreal anti VEGFs. HbA1c graded as: G1=\<7%, G2= 7-7.9%, G3= 8-8.9%, G4 = \>9%; and as: low \<8%, high ≥ 8%.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 52
- Central foveal thickness more than 250 microns
- Proliferative Diabetic Retinopathy.
- Traction Macular Membranes
- Previous Laser or intravitreal injections within 6 months.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description HBA1c Respond to therapy for diabetic macular edema -
- Primary Outcome Measures
Name Time Method Visual Acuity 3 months Correlate baseline HBA1c to the visual outcomes.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Cairo University
🇪🇬Cairo, Egypt